← Eichor
Study identifier: NCT04855773 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention

Condition: HIV Infections · Sexually Transmitted Diseases  ·  Sponsor: Public Health Foundation Enterprises, Inc.

PhaseNA
Planned participants300
Who can joinAll sexes, 15 Years to no upper limit
Healthy volunteersYes

About this study

The purpose of this study is to compare the effectiveness of two mobile health technologies (text messaging or a mobile app) designed to help people take HIV pre-exposure prophylaxis (PrEP) as directed by the clinic. PrEP is the use of a daily anti-HIV medications by HIV-negative people to help prevent HIV infection.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (4)

Bridge HIV, San Francisco Department of Public HealthSan Francisco, California, United StatesActive Not Recruiting
San Francisco AIDS FoundationSan Francisco, California, United StatesRecruiting
Whitman-Walker HealthWashington D.C., District of Columbia, United StatesRecruiting
University of MiamiMiami, Florida, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04855773